The Gloria Borges WunderGlo Foundation has given $1.3-Million Dollars directly to research funding for the cure of colorectal cancer, through 100% grass-roots funding.

The Wunder Project is a movement that was created by one doctor and one patient. A movement to get every person involved to change the face of cancer. The Gloria Borges WunderGlo Foundation continues this movement on a mission to fund vital research for the cure of colorectal cancer. Contrary to popular belief, it can be cured. The only thing standing in the way between patients and a cure is money, bureaucracy, and politics.

The Wunder Project is creative, forward-thinking, and aggressive. The Wunder Project will not back down until we have raised every last cent of the $250 MILLION DOLLARS NEEDED FOR THE CURE and we will ensure that the process will not be held up by inefficiency, middlemen, or red tape. Yes, finding the cure will be nothing short of miraculous. But this is a miracle that we can achieve and a miracle from which we can all benefit. YOU CAN BE PART OF THAT MIRACLE. EVERY PERSON, EVERY DOLLAR, EVERY DISCUSSION COUNTS. You were born to kick cancer’s ass – join Dr. Heinz-Josef Lenz, our founder, Gloria Borges, and The WunderGlo Foundation in our audacious mission to cure colon cancer.  CANCER, YOUR TIME IS UP!

  • $1.3 Million Dollars in Grants directed to Dr. Heinz-Josef Lenz at USC-Norris Comprehensive Cancer Center and to Dr. Christina Curtis at Stanford University Medical School. The Stanford grant targets urgent work/understanding the mechanisms of colorectal cancer progression.
  • THE WUNDER PROJECT RESEARCH -WunderGlo Foundation Funded Research, credited since 2015, has been published in 18-peer reviewed research papers, including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and Molecular Cancer Therapeutics.
  • The WunderGlo Foundation grants to USC-Norris Comprehensive Cancer Center and established a strategic partnership with Stanford University Medical School. The Stanford grant was directed to Dr. Christina Curtis, who’s important work is focused on understanding and characterizing the genomic determinants and dynamics of metastatic colorectal cancer towards the goal of earlier detection and intervention, as well as improved treatment stratification.
  • In 2016, through Wunder Project funding, new biomarker patents were filed at USC- Norris Comprehensive Cancer Center.

2020

Powerpoint Presentation Update on Molecular Targeted Therapies for Metastatic Colorectal Cancer by Dr. Heinz-Josef Lenz presented at GI ASCO San Francisco – January 2020.

On Tuesday, April 21st, 2020 WunderGlo Foundation Director, Dr. Heinz-Josef Lenz, MD, presented abstract research data: Molecular Landscape of Metastatic Colorectal Cancer – during Grand Rounds at USC Norris Comprehensive Cancer Center. Recent biomarker research in colorectal cancer has been remarkably progressed and assisted early drug development, especially molecular targeting agents in colon cancer. To evaluate the true value of a candidate or approved biomarker, the timing of testing and change of characterization by tumor environment such as previous treatment should be always considered when choosing patients and deciding treatment strategy. Liquid biopsy will become a standard method to non-invasively monitor dynamic changes in tumor genome during treatment that provides us better understanding about decision-making in the treatment of cancer patients. New classification such as CMS will be integrated in prospective clinical trials and hopefully speed up identification of novel therapies depending on activated pathways. Recent data showing promising results using NGS in patients with mCRC.

August 2020: In the News: WunderGlo Director, Dr. Heinz-Josef Lenz explains the exciting insight on the therapeutic approaches that are shaking up Third-Line Treatments for colorectal cancer patients. A wave of novel third-line therapeutic options have shown promising efficacy in patients with colorectal cancer (CRC), according to Heinz-Josef Lenz, MD, FACP, and refined technologies capable of detecting circulating tumor DNA (ctDNA) have opened the door to novel targets and a stronger understanding of disease biology, allowing for more informed treatment decisions. “In the third-line treatment setting for metastatic CRC, we are relying on the molecular subtyping of this disease because we understand that colon cancer is not just 1 disease. We already use the RAS mutation and we now use specific treatments for BRAFmutations,” said Lenz. “Another very interesting and important subgroup is those with HER2 overexpression and/or amplification. Several clinical trials [are examining] compounds [that are] showing very promising and exciting efficacy in this patient population.”

2019

Most Colorectal cancers have spread before diagnosis when the initial tumor is detected, according to a new Stanford study of nearly 3,000 patients by researchers at the Stanford University, led by The Wunder Project Member, Dr. Christina Curtis.  Study emphasizes that Identifying patients in whom early metastasis is likely could better guide treatment decisions.The research was supported by the National Institutes of Health (grant DP1-CA238296), the American Cancer Society, the Wunderglo Foundation, the Emerson Collective Cancer Research Fund, the Innovative Genomics Initiative and the National Cancer Institute. 

 

Cancer Discovery: Seeds of Metastatic Colorectal Cancer Are Planted Early in Disease Progression

2018

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/MicrosatelliteInstability–High Metastatic Colorectal Cancer -January 2018

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

2017

Tandem Repeat Variation Near the HIC1 (Hypermethylated in Cancer 1) Promoter Predicts Outcome of Oxaliplatin-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/ Bevacizumab or FOLFIRI/Cetuximab

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials

2016

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

2015

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach